Eloxx Pharmaceuticals has raised $24 million in a series C financing round led by Pontifax and with the participation of Catalyst CEL - Israeli Chinese fund, Quark Venture Inc. and GF Securities. Headquartered in Rehovot, Eloxx Pharmaceuticals is a clinical stage company developing first in class therapeutics to treat genetic diseases caused by non-sense mutations.
Eloxx's lead compound, ELX-02 has shown pharmacological, pharmacodynamic and physiological effects in several animal models of genetic disease cause by non-sense mutations including Cystic Fibrosis, Cystinosis, Duchene Muscular Dystrophy and Rett Syndrome.
Eloxx CEO Dr. Silvia Norman said, "This financing enables us to initiate multiple clinical studies for EL-02. We are optimistic about advancing our lead clinical programs in cystic fibrosis and cystinosis patients carrying nonsense mutations."
Last week, Eloxx merged with US company Sevion Therapeutics Inc. (OTCQB: SVON) and plans applying bto have its shares listed on Nasdaq.
Published by Globes [online], Israel business news - www.globes-online.com - on June 8, 2017
© Copyright of Globes Publisher Itonut (1983) Ltd. 2017